nbcnews.com
Hope in the fight against STIs
A surprising drop in STI diagnoses, particularly among gay and bisexual men, has brought hope to the fight against STIs. This turnaround is largely attributed to the increased adoption of doxycycline post-exposure prophylaxis (doxyPEP).
English
United States
HealthGender IssuesPublic HealthPreventionTreatmentInfectious DiseaseSti
Centers For Disease Control And Prevention (Cdc)University Of WashingtonPfizerFood And Drug Administration (Fda)Mistr
Laura BachmannJulie DombrowskiJeffrey Klausner
- What is doxyPEP and how effective is it?
- DoxyPEP, a protocol involving a single dose of doxycycline within 72 hours of condomless sex, has shown over 70% effectiveness in reducing chlamydia and syphilis cases and about 50% for gonorrhea in gay and bisexual men and transgender women.
- What are some concerns regarding the widespread use of doxyPEP?
- While doxyPEP shows promise, concerns remain about potential drug resistance and the possibility of widening racial disparities in STI transmission if access is not equitable across demographics.
- Besides doxyPEP, what other factors contributed to the decline in STI cases?
- In addition to doxyPEP, other factors contributing to the decline include increased testing among pregnant women, resolving a shortage of Bicillin-LA (syphilis treatment for pregnant women), and FDA approval of at-home STI tests.
- What is the overall trend in STI diagnoses in 2023 compared to previous years?
- The overall diagnoses of the top three bacterial STIs decreased by 2% from 2022 to 2023, reaching 2.46 million new cases. This marks a significant turning point after years of record increases.
- What is the primary factor contributing to the recent decline in syphilis diagnoses?
- The decline in STIs is largely attributed to the increased adoption of doxycycline post-exposure prophylaxis (doxyPEP) among gay and bisexual men, resulting in a 13% drop in primary and secondary syphilis diagnoses within this group.